The IFN-lambda gene family is composed of three distinct genes: IFN-lambda1 (IL-29), IFN-lambda2 (IL-28A), and IFN-lambda3 (IL-28B). IFN-lambda proteins exhibit only weak homology to IL-10, but, like IL-10, they also use the IL-10R2 chain as a component of their receptor complex. The IFN-receptor complex consists of the unique ligand-binding chain IFN- R. The IFN-lambda-1 gene is found exclusively in primate genomes and is 81% identical to IFN-lambda-2/3. IFN-lambda-s, which are now collectively referred to as type III IFNs, exhibit several features in common with type I IFNs, such as antiviral, antiproliferative, and antitumor activities.
<1.0 EU/μg of recombinant protein as determined by the LAL method.
Biological Activity Comment
The ED(50) is determined in an anti-viral assay using human HepG2 cells infected with EMCV is typically 1-5 ng/mL.
Weight
20.0 kDa
Description
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Format
Lyophilized PowderRecombinant interleukin-29 (IFN-lambda) was lyophilized from a 0.2 μm filtered 20 mM PB,130 mM NaCl solution pH 7.5.
Purity
>95% as determined by SDS-PAGE
Storage
The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.